The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 02, 2026
Snapshot (as of Oct 02, 2026): Bristol-Myers Squibb Company (BMY) pays a $2.52 annual dividend ($0.63 quarterly), yielding 4.10% at $61.46/share. Next ex-dividend date 2026-10-02. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 4.10%
Annual Dividend: $2.52 per share
Payout Ratio: 54.9%
Ex-Dividend Date: 2026-10-02
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 55
Bristol-Myers Squibb Company dividend investors are looking at a global biopharmaceutical business built around treatments like Eliquis, Opdivo, and Revlimid, spanning oncology, cardiovascular health, and immunology. The current yield is 3.98%, with a trailing annual dividend rate of $2.51 per share paid quarterly. The next ex-dividend date is October 2, 2026. With a beta of 0.227, BMY stock moves far less than the broader market, which suits income investors who prioritize low volatility over price appreciation.
Bristol-Myers Squibb Company pays out 54.9% of earnings as dividends, a payout ratio classified as moderate (40–60%). That level leaves a meaningful buffer, and the company's portfolio spans essential therapeutic areas including oncology, hematology, and cardiovascular disease, where demand is not discretionary. Bristol-Myers Squibb Company dividend safety is further supported by the breadth of its commercial lineup, though patent expirations on key products like Revlimid represent a data-supported pressure point on future revenue that could affect the payout over time.
Bristol-Myers Squibb Company dividend history shows a CAGR of 4.3% per year from 2006 to 2025. Per-share payments grew from $1.12 to $2.48 over that period (2026 is a partial year and excluded from the CAGR calculation). The largest annual increase in the window was 39.6% in 2020, though the history also contains at least one year-over-year decline exceeding 5%, so growth has not been linear. For income investors, 4.3% annual growth is meaningful but not fast.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +4.7% | $2.16 (2022) | $2.48 (2025) |
| 5-Year | +1.6% | $2.29 (2020) | $2.48 (2025) |
| 10-Year | +5.2% | $1.49 (2015) | $2.48 (2025) |
BMY stock fits income-focused investors who want a moderate yield from a large biopharmaceutical business with low price volatility. At 3.98%, the current yield sits above the 5-year average of 3.42%, meaning today's entry point offers more income than the historical norm. The yield classification is moderate (2–4%), and the 54.9% payout ratio keeps the dividend from looking stretched. The trade-off is growth: 4.3% per year over nearly two decades is real but unhurried, and the dividend history includes past declines. What BMY offers is yield above its own average, low market sensitivity, and a payout that the current earnings level supports.
| Payment Date | Amount per Share |
|---|---|
| 2026-10-02 | $0.6300 |
| 2026-07-02 | $0.6300 |
| 2026-04-02 | $0.6300 |
| 2026-01-02 | $0.6300 |
| 2025-10-03 | $0.6200 |
| 2025-07-03 | $0.6200 |
| 2025-04-04 | $0.6200 |
| 2025-01-03 | $0.6200 |
| 2024-10-04 | $0.6000 |
| 2024-07-05 | $0.6000 |
| Year | Total Dividends |
|---|---|
| 2026 | $2.5200 |
| 2025 | $2.4800 |
| 2024 | $2.4000 |
| 2023 | $2.2800 |
| 2022 | $2.1600 |
Project income from BMY with the BMY dividend calculator or track your full portfolio with the dividend tracker.